Oryzon Genomics

Oryzon Genomics EBIT

The EBIT of Oryzon Genomics (ORY.MC) as of Oct 9, 2026 is -6.42 M EUR. In the previous year, EBIT was -4.42 M EUR — a change of 45.13% (lower).

EBIT

-6.42 MEUR

YoY

45.13%

Last updated:

In 2025, Oryzon Genomics's EBIT was -6.42 M EUR, a 45.13% increase from the -4.42 M EUR EBIT recorded in the previous year.

The Oryzon Genomics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-4.55 M EUR
Jan 1, 2024
-4.42 M EUR
Jan 1, 2025
-6.42 M EUR
Jan 1, 2026 (e)
-7.00 M EUR
Jan 1, 2027 (e)
2.21 M EUR
Jan 1, 2028 (e)
80.94 M EUR
Jan 1, 2029 (e)
149.64 M EUR
Jan 1, 2030 (e)
209.58 M EUR
The Oryzon Genomics EBIT history
YEAREBITYoY
est209.58 MEUR+40.05%
est149.64 MEUR+84.87%
est80.94 MEUR+3,560.22%
est2.21 MEUR-131.61%
est-7.00 MEUR+9.01%
-6.42 MEUR+45.13%
-4.42 MEUR-2.77%
-4.55 MEUR-5.07%
-4.79 MEUR-21.75%
-6.12 MEUR+62.98%
-3.76 MEUR+12.41%
-3.34 MEUR+31.69%
-2.54 MEUR-34.36%
-3.87 MEUR-14.88%
-4.54 MEUR+1,849.65%
-233,000.00EUR-103.80%
6.12 MEUR-407.74%
-1.99 MEUR+211.16%
-639,543.00EUR—
Access this data via the Eulerpool API

Oryzon Genomics Revenue

Oryzon Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
14.19 M EUR
-4.55 M EUR
-3.35 M EUR
Jan 1, 2024
7.36 M EUR
-4.42 M EUR
-3.67 M EUR
Jan 1, 2025
0.00 EUR
-6.42 M EUR
-2.61 M EUR
Jan 1, 2026 (e)
9.00 M EUR
-7.00 M EUR
-6.51 M EUR
Jan 1, 2027 (e)
27.45 M EUR
2.21 M EUR
-470,193.45 EUR
Jan 1, 2028 (e)
113.74 M EUR
80.94 M EUR
23.00 M EUR
Jan 1, 2029 (e)
248.62 M EUR
149.64 M EUR
102.07 M EUR
Jan 1, 2030 (e)
345.17 M EUR
209.58 M EUR
143.30 M EUR

Oryzon Genomics Margins

Oryzon Genomics stock margins

The Oryzon Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oryzon Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oryzon Genomics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
98.28 %
-32.05 %
-23.63 %
Jan 1, 2024
95.90 %
-60.10 %
-49.80 %
Jan 1, 2025
95.90 %
- %
- %
Jan 1, 2026 (e)
95.90 %
-77.75 %
-72.39 %
Jan 1, 2027 (e)
95.90 %
8.06 %
-1.71 %
Jan 1, 2028 (e)
95.90 %
71.17 %
20.22 %
Jan 1, 2029 (e)
95.90 %
60.19 %
41.06 %
Jan 1, 2030 (e)
95.90 %
60.72 %
41.52 %

Oryzon Genomics Stock analysis

What does Oryzon Genomics do? The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Oryzon Genomics's EBIT

Oryzon Genomics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oryzon Genomics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oryzon Genomics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oryzon Genomics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oryzon Genomics stock

EBIT of Oryzon Genomics is -6.42 M EUR in 2025.

EBIT of Oryzon Genomics changed from -4.42 M EUR to -6.42 M EUR, representing a 45.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Oryzon Genomics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Oryzon Genomics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Oryzon Genomics

All Key Metrics — Oryzon Genomics